4D Pharma rolls on with IBS treatment and continues to look for Covid-19 test patients
With the recent sell-off in shares of 4D Pharma IGTV’s Jeremy Naylor caught up with the CEO, Duncan Peyton.
Peyton explains his thoughts on why, despite the positive results, there was a near 30% drop in the share price, of 4D Pharma, but that the company is pushing ahead with the trials that have so far proved successful. On the company’s asthma treatment, which is looking like it could double as a treatment to mitigate the worst effects of Covid-19, Peyton says it remains difficult to find patients to go onto the trials to establish the drug works as hoped.

Act on share opportunities today
Go long or short on thousands of international stocks with spread bets and CFDs.
- Get full exposure for a comparatively small deposit
- Trade on spreads from just 0.1%
- Get greater order book visibility with direct market access
See opportunity on a stock?
Try a risk-free trade in your demo account, and see whether you’re on to something.
- Log in to your demo
- Take your position
- See whether your hunch pays off
See opportunity on a stock?
Don’t miss your chance – upgrade to a live account to take advantage.
- Trade a huge range of popular stocks
- Analyse and deal seamlessly on fast, intuitive charts
- See and react to breaking news in-platform
See opportunity on a stock?
Don’t miss your chance. Log in to take advantage while conditions prevail.
Related articles
Live prices on most popular markets
- Equities
- Indices
- Forex
- Commodities
Prices above are subject to our website terms and agreements. Prices are indicative only. All share prices are delayed by at least 15 minutes.
Prices above are subject to our website terms and agreements. Prices are indicative only. All shares prices are delayed by at least 15 mins.